Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2002
10/17/2002WO2002080903A1 Functional role for cannabinoids in autonomic stability during sleep
10/17/2002WO2002080897A1 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
10/17/2002WO2002080896A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002WO2002080893A1 Treatment of low back pain and whiplash associated disorder
10/17/2002WO2002080892A1 Use of tnf inhibitor for treatment of whiplash associated disorder
10/17/2002WO2002080891A1 Use of a tnf inhibitor for the treatment of low back pain
10/17/2002WO2002080887A2 Timed pulse release composition
10/17/2002WO2002080676A1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
10/17/2002WO2002070524A3 N-but-3-enyl norbuprenorphine and its use as analgesic
10/17/2002WO2002066468A3 Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
10/17/2002WO2002066456A3 Thiophene substituted amine derivatives as glyt-1 inhibitors
10/17/2002WO2002062301A3 Method and composition for rejuvinating cells, tissues, organs, hair and nails
10/17/2002WO2002049628A3 Methods of treating anxiety disorders
10/17/2002WO2002049626A3 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity
10/17/2002WO2002047493A3 Health promoting compositions
10/17/2002WO2002042292A3 Indol derivative and their use as inhibitors of p38 kinase
10/17/2002WO2002040700A3 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
10/17/2002WO2002038607A3 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
10/17/2002WO2002036605A9 Estrone-derivatives having cytoprotective activity
10/17/2002WO2002036108A3 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases
10/17/2002WO2002034726A3 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
10/17/2002WO2002029061A3 G-protein coupled receptors
10/17/2002WO2002019213A3 Method for treatment of migraine using pde5 inhibitors
10/17/2002WO2002016417A3 Transgenic animal model for neurodegerative disease and uses thereof
10/17/2002WO2002015920A3 Treatment of hyperproliferative diseases
10/17/2002WO2002008420A3 A method of down-regulating gene expression
10/17/2002WO2001098354A3 Human receptors
10/17/2002WO2001098323A3 G-protein coupled receptors
10/17/2002WO2001091736A3 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
10/17/2002WO2001052878A9 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
10/17/2002WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002US20020152481 Genetic engineering; qualitative analysis
10/17/2002US20020152480 Alpha-synuclein super-mutants accelerate alpha-synuclein aggregation
10/17/2002US20020151716 Hydrolyzing paroxetine phenylcarbamate compound in alcohol/ hydrocarbon solvent (butanol and toluene)
10/17/2002US20020151715 Imidazole derivatives
10/17/2002US20020151698 For diagnosis, prevention, and treatment of cancer, and neurological and immune disorders
10/17/2002US20020151600 Administering a formulation containing a sesquiterpene alcohol, particularly cedrol, having a boiling atleast 250 degree C. to a person in need for regulation of autonomic nerve activity
10/17/2002US20020151596 Novel process to prepare 2-aminoindan derivatives
10/17/2002US20020151591 4-oxo-1,4-tetrahydro-1,5- naphthyridine-3-carboxamide derivative useful in treatment of disorders associated with cognition impairment including, Alzheimer's, vascular dementia, Parkinson's disease etc
10/17/2002US20020151589 Levodopa (l-dopa) ethyl ester, carbidopa or benserazide, a filler, a disintegrant, and a lubricant tablets used to treat Parkinson's disease
10/17/2002US20020151588 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects
10/17/2002US20020151585 Carbamate compounds for use in preventing or treating movement disorders
10/17/2002US20020151574 Extracellular signal regulated kinase (ERK); anticancer agents and protein kinase inhibitors
10/17/2002US20020151572 Nitric oxide synthase (NOS); alone or in combination with another active agent for the treatment of psoriasis, an antiinflammatory, an analgesic, a cognition enhancer or sleep disorder treatment
10/17/2002US20020151565 Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders
10/17/2002US20020151560 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
10/17/2002US20020151559 Analgesic combination of oxycodone and 6-MNA
10/17/2002US20020151558 Triazolo compounds as MMP inhibitors
10/17/2002US20020151557 CRF receptor antagonists and methods relating thereto
10/17/2002US20020151553 Such as 4-(4-chlorophenyl)1-(3-(5-cyano-5H-dibenzo(a,d) cycloheptene-5-yl)propyl)piperidin-4-ol for treatment of diseases associated with aberrant leukocyte recruitment and/or activation
10/17/2002US20020151547 Substituted phenyl-piperidine methanone compounds
10/17/2002US20020151538 Azepin-2-one derivatives useful for treating Alzheimer's disease
10/17/2002US20020151530 Administering to a woman, undergoing estrogen replacement therapy for treating homonal deficiences, continuously and uninterruptedly, a therapeutic effective amount of both estrogen and a non-aromatizing androgen in daily dosage
10/17/2002US20020151501 Compounds having growth hormone releasing activity
10/17/2002US20020151496 Treatment of spinal cord damage, spinal cord trauma, neuronal tissue damage produced by ischemic attack
10/17/2002US20020151488 G-CSF analog compositions and methods
10/17/2002US20020151483 C3b/C4b complement receptor-like molecules and uses thereof
10/17/2002US20020151475 Compounds and methods for modulating cell adhesion
10/17/2002US20020151464 Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
10/17/2002US20020151049 Self-enhancing, pharmacologically controllable expression systems
10/17/2002US20020151009 Human polynucleotides, polypeptides, and antibodies
10/17/2002US20020150984 Peptides for activation and inhibition of deltaPKC
10/17/2002US20020150980 Nucleotide sequences coding protein for use in the treatment of asthma, parkinson's, heart, hypotension, osteporosis and urogenital disorders
10/17/2002US20020150948 Antibody PTI-HS7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease
10/17/2002US20020150638 Solid form compositions containing an extract of a raw material as the active ingredient and process of preparing the same
10/17/2002US20020150631 Methods of treating prion disease in mammals
10/17/2002US20020150624 Mixture of drug, aminoacrylate polymer and acid
10/17/2002US20020150565 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
10/17/2002US20020150559 Binding of human antigens
10/17/2002DE10118551A1 New 2-aza-bicyclo (2.2.1) heptane derivatives, are nicotinic acetyl choline receptor ligands useful for e.g. treating schizophrenia, depression or neurodegenerative diseases
10/17/2002DE10118550A1 New 3-ethanoylamino-3-phenyl-propionic acid derivatives, are integrin agonists or antagonists useful e.g. for treating angiogenic, cardiovascular, inflammatory, osteolytic or tumor diseases or infections
10/17/2002DE10117184A1 Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen Substituted imidazol [1,2-a] pyridin-3-yl-amide, and amine compounds of
10/17/2002CA2762966A1 Hsa-free formulations of interferon-beta
10/17/2002CA2446886A1 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
10/17/2002CA2443694A1 Anti-cd19 immunotoxins
10/17/2002CA2443405A1 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002CA2443334A1 Protein modification and maintenance molecules
10/17/2002CA2443108A1 N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
10/17/2002CA2443099A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002CA2443085A1 Somatostatin agonists
10/17/2002CA2443057A1 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
10/17/2002CA2443025A1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
10/17/2002CA2442996A1 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
10/17/2002CA2442986A1 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments
10/17/2002CA2442926A1 Supercritical hydrogenation
10/17/2002CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002CA2442313A1 Methods for treating the inflammatory component of a brain disorder
10/17/2002CA2441499A1 Method for producing a vaccine
10/17/2002CA2441442A1 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002CA2440724A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002CA2440196A1 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
10/16/2002WO2001089505A1 Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
10/16/2002WO2001079186A1 2-guanidino-4-arylchinazolines as nhe-3 inhibitors
10/16/2002EP1249245A1 Remedies and/or preventives for nervous system disorders
10/16/2002EP1248849A1 Obg3 globular head and uses thereof for decreasing body mass
10/16/2002EP1248847A1 Irak-4: compositions and methods of use
10/16/2002EP1248842A1 2871 receptor, a g-protein coupled receptor and methods of use thereof
10/16/2002EP1248804A2 Recombinant antibodies to human interleukin-1 beta
10/16/2002EP1248803A2 Nogo receptor-mediated blockade of axonal growth
10/16/2002EP1248801A1 Human polynucleotides, polypeptides, and antibodies
1 ... 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 ... 1833